Saturday, June 1, 2019, Chicago, Illinois, 6:45 AM – 7:45 AM

Breakfast with the Investigators: Current and Future Management of Urothelial Bladder Carcinoma

Location:
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Time:
6:15 AM - 6:45 AM — Registration and Breakfast Buffet
6:45 AM - 7:45 AM — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty:
Daniel P Petrylak, MD
Professor of Internal Medicine (Medical Oncology) and Urology
Yale University
New Haven, Connecticut

Thomas Powles, MBBS, MRCP, MD
Professor of Genitourinary Oncology
Barts Cancer Institute
Director of Barts Cancer Centre
Queen Mary University of London
London, United Kingdom


Jonathan E Rosenberg, MD
Chief, Genitourinary Medical Oncology Service
Division of Solid Tumor Oncology
Enno W Ercklentz Chair
Memorial Sloan Kettering Cancer Center
New York, New York

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

This activity is supported by educational grants from Astellas and Seattle Genetics, AstraZeneca Pharmaceuticals LP, Genentech and Merck.
6:15 AM - 6:45 AM — Registration and Breakfast Buffet
6:45 AM - 7:45 AM — Educational Meeting

Meeting Agenda and Format

This unique activity will feature several distinct content modules during which the faculty will review available data sets, present cases from their practices and provide perspectives on key clinical questions as part of a moderated discussion. The event will not include traditional didactic lectures, and the following topics will be reviewed.

MODULE 1: Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Advanced Urothelial Bladder Carcinoma (UBC)

  • Research database supporting the FDA approvals of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab for patients with progressive metastatic UBC; patient selection for and use of these agents in clinical practice
  • Rapidity, likelihood and durability of response with anti-PD-1/PD-L1 antibodies compared to second-line chemotherapy for patients with metastatic UBC experiencing disease progression on platinum-based chemotherapy
  • Rationale for and clinical implications of recent revision of FDA approvals of atezolizumab and pembrolizumab limiting their use for patients with metastatic UBC who have not received prior therapy, are not eligible for cisplatin-containing treatment or who have low expression of PD-L1
  • Available platforms to assess PD-L1 status in patients with metastatic UBC; other potential predictors of response to anti-PD-1/PD-L1 therapy
  • Frequency, recognition and management of immune-mediated adverse events in patients receiving anti-PD-1/PD-L1 antibodies for metastatic UBC

MODULE 2: Newly Approved and Investigational Novel Agents and Strategies Beyond Immune Checkpoint Inhibition

  • Frequency of FGFR alterations in patients with metastatic UBC; mechanism of action of erdafitinib
  • Efficacy and safety data supporting the recent FDA approval of erdafitinib for patients with locally advanced or metastatic UBC with susceptible FGFR3 or FGFR2 genetic alterations who have experienced disease progression on or after chemotherapy
  • Optimal integration of erdafitinib into current clinical management
  • Biologic rationale for targeting nectin-4 in patients with metastatic UBC; structural components and mechanism of antitumor response of the antibody-drug conjugate enfortumab vedotin
  • Documented response rates and spectrum of toxicities observed in early trials of enfortumab vedotin; FDA breakthrough therapy designation
  • Design, entry criteria and emerging data from the pivotal Phase II EV-201 trial evaluating enfortumab vedotin in patients with locally advanced or metastatic UBC who previously received immune checkpoint inhibitor therapy
  • Ongoing studies evaluating the use of enfortumab vedotin in combination with other systemic therapies, including anti-PD-1/PD-L1 antibodies (eg, EV-103)
  • Other promising novel agents and strategies currently under evaluation for metastatic UBC

MODULE 3: Future Applications of Anti-PD-1/PD-L1 Antibodies Alone or in Combination with Other Systemic Approaches

  • Published data sets with the use of chemotherapy in combination with an anti-PD-1/PD-L1 antibody for patients with metastatic UBC; ongoing Phase III trials evaluating this approach in the up-front setting
  • Rationale for the design of trials investigating the use of anti-PD-1/PD-L1 antibodies as maintenance treatment after completion of first-line chemotherapy
  • Available data with and ongoing evaluation of regimens combining anti-PD-1/PD-L1 antibodies with anti-CTLA-4 antibodies or other systemic therapies for metastatic UBC
  • Rates of pathologic complete response and other clinically relevant endpoints achieved in studies evaluating neoadjuvant anti-PD-1/PD-L1 therapy for muscle-invasive, resectable UBC
  • Phase III trials attempting to determine the potential utility and safety of anti-PD-1/PD-L1 antibodies as adjuvant therapy for patients with localized UBC after partial or complete cystectomy
  • Current efforts investigating the role of anti-PD-1/PD-L1 antibodies for patients with nonmuscle-invasive UBC that is unresponsive or refractory to BCG therapy

Target Audience:
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of bladder cancer.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Appraise recent data on diagnostic and therapeutic advances in urothelial bladder cancer (UBC), and integrate this information, as appropriate, into current clinical care.
  • Compare and contrast the available clinical trial evidence with the use of immune checkpoint inhibitors for the treatment of UBC to determine the current utility of these agents in clinical practice.
  • Appreciate recent revisions to the FDA approvals of atezolizumab and pembrolizumab limiting the use of these agents for patients with locally advanced or metastatic UBC who have not received prior therapy, are not eligible for cisplatin-containing treatment or who have low expression of PD-L1.
  • Describe ongoing research to assist in the identification of biomarkers, tumor characteristics or other clinical features that are predictive of response to immune checkpoint inhibitors in patients with UBC.
  • Recognize immune-related adverse events and other common side effects associated with approved immune checkpoint inhibitors, and use this information to develop supportive management plans for patients with UBC undergoing treatment with these agents.
  • Consider available and emerging data with anti-PD-1/PD-L1 antibodies alone in earlier disease settings or in combination with other systemic approaches, and refer eligible patients for appropriate trial participation.
  • Recognize the mechanisms of action and available trial data with approved and investigational novel targeted agents with activity in patients with relapsed/refractory UBC to determine the current or future utility of these agents in practice.
  • Recall new data with other investigational agents and strategies demonstrating promising activity in UBC, and discuss ongoing trial opportunities with eligible patients.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from Astellas and Seattle Genetics, AstraZeneca Pharmaceuticals LP, Genentech and Merck.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 

This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of bladder cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.